Sodium-glucose co-transporter 2 (SGLT2) inhibitor (SGLT2i) is a novel class of anti-diabetic drug, which has displayed a promising benefit for non-alcoholic fatty liver disease (NAFLD). This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.